Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Getinge AB
  6. News
  7. Summary
    GETI B   SE0000202624

GETINGE AB

(GETI B)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe Europe - 01/28 11:29:45 am
351 SEK   +4.78%
03:46aGETINGE : Presentation Full Year Report 2021
PU
03:46aGETINGE : See presentation
PU
02:01aGETINGE YEAR END REPORT 2021 : "Healthy order growth, improved EBITA margin and strong cash flow"
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Medical kit maker Getinge raises targets, citing COVID impact

11/22/2021 | 07:51am EST

STOCKHOLM, Nov 22 (Reuters) - Swedish medical equipment supplier Getinge on Monday raised its financial targets for 2022-2025 as positive effects of the COVID-19 pandemic are felt across its business.

Getinge Chief Executive Mattias Perjos said hospitals taking on surgeries postponed due to the coronavirus pandemic, infection control becoming increasingly important, and the COVID-19 vaccination roll-out would help drive sales, as well as underlying demand growth seen already before the pandemic.

"We have tried to see through all the moving parts and dust that the pandemic has stirred up and form an opinion on our end-markets," Perjos told Reuters.

"On average we see that growth is accelerating and our entire portfolio is gravitating towards higher-growth markets such as ECMO, sterile transfer and biopharmaceutical research and production," he added.

Getinge said in a statement ahead of investor presentations that it aimed to grow adjusted earnings per share by 10% annually on the back of a widening of its operating profit before amortisation margin to 21% or more by the end of the period, and annual like-for-like sales growth of 4-6%.

Getinge's previous targets were for a 10% rise in earnings per share and organic sales growth of 2-4%. In the 2018–2020 period, organic sales were up 9.9%, while earnings grew 22.4%.

In 2020, Getinge's organic sales jumped 14% due to strong demand for advanced intensive care unit ventilators and products such as extracorporeal membrane oxygenation (ECMO) machines - a kind of artificial lung used in the treatment of COVID patients.

Its earnings per share roughly doubled to 14.43 crowns, while the margin increased to 19.2% from 12.5%.

Shares in Getinge were up 0.4% at 1510 GMT. (Reporting by Anna Ringstrom; Editing by Niklas Pollard and Alexander Smith)


ę Reuters 2021
All news about GETINGE AB
03:46aGETINGE : Presentation Full Year Report 2021
PU
03:46aGETINGE : See presentation
PU
02:01aGETINGE YEAR END REPORT 2021 : "Healthy order growth, improved EBITA margin and strong cas..
AQ
01/26GETINGE : A strong history of building world-class operating tables
PU
01/19GETINGE : Cloud-based software solutions to support healthcare delivery
PU
01/17Getinge appoints Patricia Fitch as President North America Region
AQ
01/17Getinge appoints Elin Frostehav as President Acute Care Therapies and Eric Honroth as P..
AQ
01/17Getinge AB Appoints Elin Frostehav as President Acute Care Therapies and Eric Honroth a..
CI
01/17Getinge AB Announces Executive Changes, Effective April 1, 2022
CI
01/17GETINGE AB : Nomination
CO
More news
Analyst Recommendations on GETINGE AB
More recommendations
Financials
Sales 2021 27 386 M 2 903 M 2 903 M
Net income 2021 2 958 M 314 M 314 M
Net Debt 2021 4 221 M 448 M 448 M
P/E ratio 2021 32,3x
Yield 2021 0,92%
Capitalization 95 602 M 10 144 M 10 136 M
EV / Sales 2021 3,64x
EV / Sales 2022 3,35x
Nbr of Employees 10 667
Free-Float 79,8%
Chart GETINGE AB
Duration : Period :
Getinge AB Technical Analysis Chart | GETI B | SE0000202624 | MarketScreener
Technical analysis trends GETINGE AB
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 351,00 SEK
Average target price 418,20 SEK
Spread / Average Target 19,1%
EPS Revisions
Managers and Directors
Mattias Sven Perjos President, Chief Executive Officer & Director
Lars Sandstr÷m Chief Financial Officer
Johan Malmquist Chairman
Anna Romberg Executive VP-Legal, Compliance & Governance
Johan Bygge Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GETINGE AB-15.21%9 743
MASIMO CORPORATION-31.86%11 016
PENUMBRA, INC.-31.26%7 378
NOVOCURE LIMITED-16.17%6 245
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.-21.11%4 645
SHOCKWAVE MEDICAL, INC.-28.25%4 518